MX2018000464A - Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia. - Google Patents
Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia.Info
- Publication number
- MX2018000464A MX2018000464A MX2018000464A MX2018000464A MX2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A
- Authority
- MX
- Mexico
- Prior art keywords
- adrenoleukodystrophy
- treatment
- diagnosis
- compositions
- methods
- Prior art date
Links
- 201000011452 Adrenoleukodystrophy Diseases 0.000 title abstract 4
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 title abstract 4
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000012544 monitoring process Methods 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382366.1A EP3118621A1 (en) | 2015-07-14 | 2015-07-14 | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| PCT/EP2016/066825 WO2017009437A1 (en) | 2015-07-14 | 2016-07-14 | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018000464A true MX2018000464A (es) | 2018-09-06 |
Family
ID=53776537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000464A MX2018000464A (es) | 2015-07-14 | 2016-07-14 | Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190010535A1 (enExample) |
| EP (2) | EP3118621A1 (enExample) |
| JP (1) | JP2018529081A (enExample) |
| KR (1) | KR20180030074A (enExample) |
| CN (1) | CN107923897A (enExample) |
| AU (1) | AU2016293068A1 (enExample) |
| BR (1) | BR112018000749A2 (enExample) |
| CA (1) | CA2991586A1 (enExample) |
| CL (1) | CL2018000078A1 (enExample) |
| HK (1) | HK1253769A1 (enExample) |
| MX (1) | MX2018000464A (enExample) |
| WO (1) | WO2017009437A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US12172017B2 (en) * | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US11958805B2 (en) * | 2017-03-09 | 2024-04-16 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| US12276670B2 (en) | 2017-09-29 | 2025-04-15 | The General Hospital Corporation | Methods for identifying and treating adrenomyeloneuropathy (AMN) |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| KR102252167B1 (ko) * | 2018-11-22 | 2021-05-17 | 연세대학교 산학협력단 | X-연관 부신백질이영양증 진단용 바이오마커 조성물 |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| FR3132910A1 (fr) * | 2022-02-24 | 2023-08-25 | Universite De Bourgogne | Methodes pour le pronostic et le suivi des leucodystrophies peroxysomales |
| EP4431945A1 (en) * | 2023-03-16 | 2024-09-18 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Biomarkers discriminating the discordant phenotypes of x-adrenoleukodystrophy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1355193A (zh) * | 2000-12-01 | 2002-06-26 | 复旦大学 | 一种新的多肽——肾上腺脑白质营养不良相关蛋白10.78和编码这种多肽的多核苷酸 |
| CA2752003A1 (en) | 2009-02-24 | 2010-09-02 | Novartis Ag | Ceramide-analogous metabolites |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| ES2377381B1 (es) * | 2010-05-17 | 2013-03-14 | Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) | Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes. |
| JP2013533286A (ja) * | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
| WO2012112933A1 (en) * | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| AU2014205529B2 (en) * | 2013-01-08 | 2018-08-09 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
| JP2016519684A (ja) * | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
-
2015
- 2015-07-14 EP EP15382366.1A patent/EP3118621A1/en not_active Withdrawn
-
2016
- 2016-07-14 US US15/745,199 patent/US20190010535A1/en not_active Abandoned
- 2016-07-14 CN CN201680041132.6A patent/CN107923897A/zh active Pending
- 2016-07-14 JP JP2018502150A patent/JP2018529081A/ja active Pending
- 2016-07-14 BR BR112018000749A patent/BR112018000749A2/pt not_active IP Right Cessation
- 2016-07-14 AU AU2016293068A patent/AU2016293068A1/en not_active Abandoned
- 2016-07-14 WO PCT/EP2016/066825 patent/WO2017009437A1/en not_active Ceased
- 2016-07-14 MX MX2018000464A patent/MX2018000464A/es unknown
- 2016-07-14 EP EP16739131.7A patent/EP3322980B1/en active Active
- 2016-07-14 CA CA2991586A patent/CA2991586A1/en not_active Abandoned
- 2016-07-14 HK HK18107651.5A patent/HK1253769A1/zh unknown
- 2016-07-14 KR KR1020187003374A patent/KR20180030074A/ko not_active Withdrawn
-
2018
- 2018-01-10 CL CL2018000078A patent/CL2018000078A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3322980B1 (en) | 2020-09-09 |
| AU2016293068A1 (en) | 2018-02-01 |
| EP3322980A1 (en) | 2018-05-23 |
| EP3118621A1 (en) | 2017-01-18 |
| HK1253769A1 (zh) | 2019-07-05 |
| JP2018529081A (ja) | 2018-10-04 |
| CA2991586A1 (en) | 2017-01-19 |
| US20190010535A1 (en) | 2019-01-10 |
| CN107923897A (zh) | 2018-04-17 |
| CL2018000078A1 (es) | 2018-07-06 |
| KR20180030074A (ko) | 2018-03-21 |
| BR112018000749A2 (pt) | 2018-09-04 |
| WO2017009437A1 (en) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000464A (es) | Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia. | |
| PH12016502256A1 (en) | Medical use | |
| GB2569921A (en) | Bisymmetric comparison of sub-epidermal moisture values | |
| SG10201903823QA (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| MX2015015907A (es) | Metodo no invasivo objetivo para cuantificar el grado de comezon mediante el uso de mediciones psicofisiologicas. | |
| MY192055A (en) | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| FI20166026L (fi) | Jäljityskappaleet leuan kovakudoksen liikkeiden jäljittämiseksi | |
| WO2015197193A3 (en) | New use for jnk inhibitor molecules for treatment of various diseases | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| MA40535A (fr) | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 | |
| EP3432778C0 (en) | DEVICE AND METHOD FOR LOCALIZING, MEASURING AND MONITORING INFLAMMATION OF SOFT TISSUE OF THE SKIN | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| WO2014200969A3 (en) | Methods of treatment of cancer | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX376087B (es) | Inhibidores macrocíclicos de cinasa rip2. | |
| IL248935A0 (en) | Diagnostic testing and treatment/prevention of Alzheimer's disease | |
| TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2017002628A (es) | Dispositivo de visualizacion de imagenes sobre superficies de modelos anatomicos y metodo relacionado. | |
| AU2018904175A0 (en) | Methods of treatment, prevention and diagnosis | |
| HK40007979A (en) | System for characterization, diagnosis, and treatment of a health condition of a patient and methods of using same |